![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.125 | 10.75 | 11.50 | 11.125 | 11.125 | 11.13 | 194,022 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -8.62 | 103.17M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/5/2023 10:05 | Thanks Super. | ![]() torquayfan | |
02/5/2023 10:03 | tf - not, I don't think, the NHS. Your local trust? | ![]() supernumerary | |
02/5/2023 09:02 | I wonder if Pfizer`s $43 B acquisition of Seagen will delay an Avidimab deal if one is in the works ? | ![]() marcusl2 | |
02/5/2023 08:50 | Promising activity in CD40 based preclinical models CD40 (cluster of differentiation 40) agonists are a promising area in immunooncology as they increase the number and quality of tumour-infiltrating T cells. Theoretically they should be highly effective as a monotherapy or to reverse resistance to checkpoint-blocking antibodies. However, preclinical potency has not yet been replicated in the clinical setting and none of these mAbs have advanced beyond early trial phases. One of the challenges encountered was insufficient immune activation, which resulted in antitumor efficacy only becoming apparent at toxic doses. SEA-CD40 (Seagen) is in Phase II trials for advanced solid tumours. AvidiMab was used in the Fc region (Exhibit 5) in an IgG1 format, with key residues from murine IgG3 transferred into the human SEA-CD40 IgG1 Fc region. The results for iSEACD40 showed higher Fc-Fc self-association, slower off-rate and improved binding to CD40, and better functional affinity than original SEA-CD40. These findings of better performance were also seen in other immune models that rely on clustering and/or increased residence time for activity. Preclinical work continues to highlight the versatility and broad applicability of the AvidiMab platform, with sizable improvements seen across many applications. | ![]() marcusl2 | |
01/5/2023 20:10 | Tell it to yourself when you over 90. In the meantime all we see is red. | golcheja | |
01/5/2023 20:08 | Scancell covid vaccine was close to a flop not sure why the continuous association between Scancell and covid, no return is coming from this direction. | golcheja | |
01/5/2023 15:35 | Inan - just an update - the NHS are now advising the likes of me, i.e. 75 and over, that you have to book your next Covid booster THIS week - or not at all. I've seen nothing about this in Parliament or media - this might be Wiltshire only but I'm not sure. MMmm ? | ![]() torquayfan | |
01/5/2023 15:10 | Inane, "when did the WHO get all this power ........ ? they might consider asking".. You are so ignorant it is frightening, why don't you do some research " The WHO Pandemic Treaty " and the changes to the " 2005 IHR " International Health Regulations that our Government is happy to sign up to. | ![]() panama7 | |
01/5/2023 14:29 | European Big Pharmas hint M&A could ramp up With today's $ISEE deal, nearly $65 billion in announced biopharmaceutical dealmaking in March and April: | ![]() marcusl2 | |
01/5/2023 14:11 | “You don’t have to be brilliant, only a little bit wiser than the other guys, on average, for a long time” “The big money is not in the buying and selling but in the waiting” Charlie Munger | ![]() marcusl2 | |
01/5/2023 09:17 | Marcus the SCIB1 antibody does not target cancer .... it targets Dendritic cells via two paths as a plasmid it breaks into the Dendritic cell using the "device" the same plasmid which breaks into a muscle cell turns the cell into a antibody factory, those antibodies then target the dendritic cell again via its CD64 receptor this gives the dendritic cell two signals this is what induces High Avidity t cells that engage that Dendritic cell All vaccines target the dendritic cell .. but i have seen no vaccine that does it like immunobody Modi1 is taken up by dendritic cells ......... that gives you a first signal t cell ....... the second signal to fully activate than comes from Dendritic cells in the cancer that dendritic cell has already acquired the citrullinated peptide but not from the vaccine but the cancer the cancer "suppresses that dendritic cell" so the t cell never get the first signal from it scancell activates the first signal ............ this is why we are getting impressive results i keep trying to explain that the vaccine has proven itself .. what we are trialing is the "t cell" don't listen to all this nonsense that somehow it could fail ..... 23 out of 23 have that acknowledgement, that the vaccine has induced a potent t cell what nobody has ever done is looked at the results from it ........ !! so the research is the CD4 Killer T cell ............ Modi1 works | ![]() inanaco | |
30/4/2023 23:54 | MT - re. Bridgen - as Sir Humphrey said, 'beautifully argued'! My usual bias ? I try to be interested in the message, wherever it comes from. Inan - wasting my life Inan ? My weekend outings are infrequent to say the least. Nice day to you. | ![]() torquayfan | |
30/4/2023 22:00 | Marking time/ Empty vessel you are so deluded and pompous you really need to take a look at yourself in the mirror, I thought the share price would be 40p by the end of the month shows how much you know and how seriously deluded you are. It would appear Bridgen knows what he is talking about compared to you. | ![]() panama7 | |
30/4/2023 21:54 | Marking time/ Empty vessel very interesting viewpoint bearing in mind Bridgen has been quoting the governments own figures. are you saying the ONS are lying or is it that you are living in denial of the truth. The WHO changes to IHR state that they propose to remove individual human rights are you saying that the WHO are lying ? | ![]() panama7 | |
30/4/2023 15:20 | Bridgen is a pompous idiot. Period.Surprising you support him, considering your usual bias.... | ![]() markingtime | |
30/4/2023 15:00 | OK MT. That's very dismissive and with such authority ? You think the WHO taking control of all Member States next pandemic strategy, hangs together as a good idea? MMmmm That's one to Bridgen then. He has a better chance of winning that seat as an Independent maybe. ATB | ![]() torquayfan | |
30/4/2023 14:02 | Bridgen hasn't had any messages of importance for at least 7 years. He has been showing increasingly-poor judgement on a very wide range of issues and hopefully will soon be consigned to obscurity in Leicestershire. | ![]() markingtime | |
30/4/2023 13:30 | Yes Small Crow. JC is a DR/PhD in nursing. Thanks I get that. I don't watch JC much but sometimes, I think he's helpful. I'd guess that Bridgen in his quote knows quite well that JC is not by qualifications, 'a great and respected expert', but that JC has made himself in that image, being visible with his sometimes helpful efforts - a sort of 'broker' in the field. The other bit about 'JC is a true ally etc. etc.' is probably true. But again, let's look at the messages around this, rather than the messengers. ATB | ![]() torquayfan | |
30/4/2023 12:47 | TF, Just pointing out, it seems that Campbell's qualification is in Nursing and not a research doctorate in virology? Despite this, Bridgen writes: "Andrew Bridgen @ABridgen · 18h Many thanks to Dr John Campbell -- a great and respected expert in the field of vaccines and immunology, and a true ally in our fight for justice for the injured and bereaved." I'm pretty sure he is neither of these things, but I'm not going to waste time arguing with the internet .... | ![]() small crow |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions